AGEN
Price:
$2.7101
Market Cap:
$63.58M
Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs comprising Prophage vaccine candidate; and QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an anti-CTLA-4 monospecific antibody that is in Phase 1/2 clinical trial; AGEN2373, an anti-CD137 m...[Read more]
Industry
Biotechnology
IPO Date
2000-02-08
Stock Exchange
NASDAQ
Ticker
AGEN
According to Agenus Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -0.25. This represents a change of -78.90% compared to the average of -1.18 of the last 4 quarters.
The mean historical PE Ratio of Agenus Inc. over the last ten years is -3.42. The current -0.25 PE Ratio has changed 630.86% with respect to the historical average. Over the past ten years (40 quarters), AGEN's PE Ratio was at its highest in in the March 2019 quarter at 6.07. The PE Ratio was at its lowest in in the September 2015 quarter at -7.41.
Average
-3.42
Median
-2.74
Minimum
-7.78
Maximum
-1.21
Discovering the peaks and valleys of Agenus Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 240.75%
Maximum Annual PE Ratio = -1.21
Minimum Annual Increase = -68.01%
Minimum Annual PE Ratio = -7.78
Year | PE Ratio | Change |
---|---|---|
2023 | -1.21 | -51.58% |
2022 | -2.49 | -68.01% |
2021 | -7.78 | 240.75% |
2020 | -2.28 | -37.99% |
2019 | -3.68 | 123.13% |
2018 | -1.65 | -37.90% |
2017 | -2.66 | -5.89% |
2016 | -2.82 | -30.09% |
2015 | -4.04 | -27.64% |
2014 | -5.58 | 113.68% |
The current PE Ratio of Agenus Inc. (AGEN) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-3.83
5-year avg
-3.49
10-year avg
-3.42
Agenus Inc.’s PE Ratio is greater than Icosavax, Inc. (-15.78), less than Galera Therapeutics, Inc. (-0.08), greater than Marker Therapeutics, Inc. (-3.20), greater than Edgewise Therapeutics, Inc. (-22.33), greater than Adaptimmune Therapeutics plc (-3.32), greater than Mereo BioPharma Group plc (-13.78), greater than Pieris Pharmaceuticals, Inc. (-1.13), greater than PDS Biotechnology Corporation (-1.49), greater than Leap Therapeutics, Inc. (-1.84), greater than Viking Therapeutics, Inc. (-47.21), greater than TG Therapeutics, Inc. (-324.72), greater than X4 Pharmaceuticals, Inc. (-7.12), greater than Madrigal Pharmaceuticals, Inc. (-13.07), greater than TCR2 Therapeutics Inc. (-0.38), greater than Affimed N.V. (-0.26), greater than ADC Therapeutics SA (-0.99),
Company | PE Ratio | Market cap |
---|---|---|
-15.78 | $769.04M | |
-0.08 | $1.64M | |
-3.20 | $30.88M | |
-22.33 | $2.80B | |
-3.32 | $149.13M | |
-13.78 | $585.13M | |
-1.13 | $17.96M | |
-1.49 | $61.35M | |
-1.84 | $110.74M | |
-47.21 | $4.70B | |
-324.72 | $5.00B | |
-7.12 | $101.30M | |
-13.07 | $6.80B | |
-0.38 | $58.11M | |
-0.26 | $19.03M | |
-0.99 | $193.38M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Agenus Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Agenus Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Agenus Inc.'s PE Ratio?
How is the PE Ratio calculated for Agenus Inc. (AGEN)?
What is the highest PE Ratio for Agenus Inc. (AGEN)?
What is the 3-year average PE Ratio for Agenus Inc. (AGEN)?
What is the 5-year average PE Ratio for Agenus Inc. (AGEN)?
How does the current PE Ratio for Agenus Inc. (AGEN) compare to its historical average?